Neonatal Fc Receptor Blocker [EPC]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Neonatal Fc Receptor Blocker [EPC] includes 2 drugs with a combined 552 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
552
Combined Reports
All Neonatal Fc Receptor Blocker [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| ROZANOLIXIZUMAB | RYSTIGGO | 303 | 9 | 114 | 3.0% |
| EFGARTIGIMOD ALFA | VYVGART | 249 | 26 | 115 | 10.4% |
Common Side Effects in Neonatal Fc Receptor Blocker [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Myasthenia gravis | 204 | 3 |
| Drug ineffective | 79 | 3 |
| Headache | 77 | 0 |
| Fatigue | 56 | 0 |
| Diarrhoea | 49 | 0 |
| Off label use | 47 | 1 |
| Asthenia | 46 | 0 |
| Dyspnoea | 42 | 1 |
| Myasthenia gravis crisis | 38 | 0 |
| Nausea | 32 | 0 |